Screener
Roivant Sciences ROIV Net gains (losses) on investments
Net gains (losses) on investments at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Roivant Sciences in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnInvestments.
The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001635088-26-000090
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 |
|---|---|---|
| Total operating expenses | 367,827 | 287,092 |
| Gain on litigation settlement | 392 | — |
| Loss from operations | (365,993) | (284,922) |
| Change in fair value of investments | (36,637) | 19,125 |
| Change in fair value of liability instruments | — | 2,329 |
| Interest income | (36,922) | (48,322) |
| Other expense, net | 2,130 | 11,208 |
| Loss before income taxes | (294,564) | (269,262) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Roivant Sciences's net gains (losses) on investments?
- Roivant Sciences (ROIV) reported net gains (losses) on investments of $36.64M in Q2 2026.
- How has Roivant Sciences's net gains (losses) on investments changed year-over-year?
- Roivant Sciences's net gains (losses) on investments increased by 291.6% year-over-year, from -$19.13M to $36.64M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Roivant Sciences's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude